Anti-WT1/HLA bi-specific antibody

A recombinant antibody comprising:

• (i) a first antigen-binding portion comprising:
• (A) a heavy chain (HC) variable region comprising HC-CDR1, HC-CDR2 and HC-CDR3, and a light chain (LC) variable region comprising LC-CDR1, LC-CDR2 and LC-CDR3, wherein:
• (1) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 2, 3, and 4, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 8, 9, and 10, respectively;
• (2) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 20, 21, and 22, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 26, 27, and 28, respectively;
• (3) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 38, 39, and 40, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 44, 45, and 46, respectively;
• (4) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 56, 57, and 58, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 62, 63, and 64, respectively;
• (5) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 92, 93, and 94, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 80, 81, and 82, respectively;
• or
• (5) the HC-CDR1, HC-CDR2 and HC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 74, 75, and 76, respectively, and the LC-CDR1, LC-CDR2 and LC-CDR3 comprises amino acid sequences set forth in SEQ ID NOs:
• 98, 99, and 100, respectively;
• (B) a VH and a VL comprising first and second amino acid sequences as set forth in SEQ ID NOs:
• 14 and 16, 32 and 34, 50 and 52, 68 and 70, 86 and 88, or 104 and 106;
• or
• (C) an scFv comprising an amino acid sequence as set forth in SEQ ID NO:
• 18, 36, 54, 72, 90, or 108;
• and
• (ii) a second antigen-binding portion comprising an amino acid sequence set forth in SEQ ID NO:
• 111, 112, or 113.